Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome--11beta-hydroxysteroid dehydrogenase type 1.
作者信息
Stewart Paul M
机构信息
Division of Medical Sciences, Institute of Biomedical Research, Medical School, University of Birmingham.
出版信息
Clin Med (Lond). 2005 Mar-Apr;5(2):142-6. doi: 10.7861/clinmedicine.5-2-142.
Abstract
摘要
相似文献
1
Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome--11beta-hydroxysteroid dehydrogenase type 1.组织特异性库欣综合征揭示了治疗代谢综合征的新靶点——11β-羟类固醇脱氢酶1型。
Clin Med (Lond). 2005 Mar-Apr;5(2):142-6. doi: 10.7861/clinmedicine.5-2-142.
2
Adipose tissue expression of 11beta-hydroxysteroid dehydrogenase type 1 in Cushing's syndrome and in obesity.库欣综合征和肥胖症中11β-羟基类固醇脱氢酶1型的脂肪组织表达
Arq Bras Endocrinol Metabol. 2007 Nov;51(8):1397-403. doi: 10.1590/s0004-27302007000800027.
3
11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.11β-羟类固醇脱氢酶 1 型：其在肥胖症、代谢综合征和 2 型糖尿病病理生理学中的调节作用。
Diabetes Obes Metab. 2012 Oct;14(10):869-81. doi: 10.1111/j.1463-1326.2012.01582.x. Epub 2012 Mar 8.
4
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.组织特异性糖皮质激素激活酶，11β-羟基类固醇脱氢酶1型（11β-HSD1）——治疗代谢综合征的一个有前景的药物靶点。
Curr Drug Targets Immune Endocr Metabol Disord. 2003 Dec;3(4):255-62. doi: 10.2174/1568008033340135.
5
Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both?用于代谢综合征患者的11β-羟类固醇脱氢酶1型选择性抑制剂：靶点是肝脏、脂肪还是两者兼而有之？
Diabetes. 2009 Jan;58(1):14-5. doi: 10.2337/db08-1404.
6
11beta-hydroxysteroid dehydrogenase type 1 and obesity.11β-羟类固醇脱氢酶1型与肥胖症
Front Horm Res. 2008;36:146-164. doi: 10.1159/000115363.
7
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.肥胖与代谢综合征中的糖皮质激素及11β-羟类固醇脱氢酶1型
Minerva Endocrinol. 2007 Sep;32(3):141-59.
8
11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes.11β-羟类固醇脱氢酶 1 型抑制剂治疗 2 型糖尿病。
Expert Opin Investig Drugs. 2010 Sep;19(9):1067-76. doi: 10.1517/13543784.2010.504713.
9
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.脂肪组织中的糖皮质激素与11β-羟基类固醇脱氢酶
Recent Prog Horm Res. 2004;59:359-93. doi: 10.1210/rp.59.1.359.
10
Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1.普通狨猴代谢综合征的产前编程与11β-羟基类固醇脱氢酶1型表达增加有关。
Diabetes. 2009 Dec;58(12):2873-9. doi: 10.2337/db09-0873. Epub 2009 Aug 31.
引用本文的文献
1
Chronic glucocorticoid exposure-induced epididymal adiposity is associated with mitochondrial dysfunction in white adipose tissue of male C57BL/6J mice.长期暴露于糖皮质激素诱导的附睾脂肪增多与雄性C57BL/6J小鼠白色脂肪组织中的线粒体功能障碍有关。
PLoS One. 2014 Nov 12;9(11):e112628. doi: 10.1371/journal.pone.0112628. eCollection 2014.
2
TNFα-mediated Hsd11b1 binding of NF-κB p65 is associated with suppression of 11β-HSD1 in muscle.TNFα 介导的 NF-κB p65 与 Hsd11b1 的结合与肌肉中 11β-HSD1 的抑制有关。
J Endocrinol. 2014 Feb 10;220(3):389-96. doi: 10.1530/JOE-13-0494. Print 2014 Mar.
3
Glucocorticoids and type 2 diabetes: from physiology to pathology.糖皮质激素与2型糖尿病：从生理到病理
J Nutr Metab. 2012;2012:525093. doi: 10.1155/2012/525093. Epub 2012 Dec 18.
4
Relationship between type 2 diabetes mellitus and hypothalamic-pituitary-adrenal axis.2 型糖尿病与下丘脑-垂体-肾上腺轴的关系。
Wien Klin Wochenschr. 2011 Jan;123(1-2):28-33. doi: 10.1007/s00508-010-1497-8. Epub 2010 Dec 20.
Zotero 插件